Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin

Davide Cervia, Emma Assi, Clara De Palma, Matteo Giovarelli, Laura Bizzozero, Sarah Pambianco, Ilaria Di Renzo, Silvia Zecchini, Claudia Moscheni, Chiara Vantaggiato, Patrizia Procacci, Emilio Clementi, Cristiana Perrotta

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The sphingolipid metabolising enzyme Acid Sphingomyelinase (A-SMase) has been recently shown to inhibit melanoma progression and correlate inversely to tumour grade. In this study we have investigated the role of A-SMase in the chemo-resistance to anticancer treatment using mice with melanoma allografts and melanoma cells differing in terms of expression/activity of A-SMase. Since autophagy is emerging as a key mechanism in tumour growth and chemo-resistance, we have also investigated whether an action of A-SMase in autophagy can explain its role. Melanoma sensitivity to chemotherapeutic agent cisplatin in terms of cell viability/apoptosis, tumour growth, and animal survival depended directly on the A-SMase levels in tumoural cells. A-SMase action was due to inhibition of autophagy through activation of Akt/mammalian target of rapamycin (mTOR) pathway. Treatment of melanoma-bearing mice with the autophagy inhibitor chloroquine restored sensitivity to cisplatin of tumours expressing low levels of A-SMase while no additive effects were observed in tumours characterised by sustained A-SMase levels. The fact that A-SMase in melanomas affects mTOR-regulated autophagy and plays a central role in cisplatin efficacy encourages pre-clinical testing on the modulation of A-SMase levels/activity as possible novel anti-neoplastic strategy.

Original languageEnglish
Pages (from-to)24995-25009
Number of pages15
JournalOncotarget
Volume7
Issue number18
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Sphingomyelin Phosphodiesterase
Autophagy
Cisplatin
Melanoma
Acids
Sirolimus
Neoplasms
Sphingolipids
Chloroquine
Growth
Allografts
Cell Survival
Apoptosis

Keywords

  • A-SMase
  • Autophagy
  • Chemo-resistance
  • Melanoma
  • mTOR

ASJC Scopus subject areas

  • Oncology

Cite this

Cervia, D., Assi, E., De Palma, C., Giovarelli, M., Bizzozero, L., Pambianco, S., ... Perrotta, C. (2016). Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin. Oncotarget, 7(18), 24995-25009. https://doi.org/10.18632/oncotarget.8735

Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin. / Cervia, Davide; Assi, Emma; De Palma, Clara; Giovarelli, Matteo; Bizzozero, Laura; Pambianco, Sarah; Di Renzo, Ilaria; Zecchini, Silvia; Moscheni, Claudia; Vantaggiato, Chiara; Procacci, Patrizia; Clementi, Emilio; Perrotta, Cristiana.

In: Oncotarget, Vol. 7, No. 18, 01.05.2016, p. 24995-25009.

Research output: Contribution to journalArticle

Cervia, D, Assi, E, De Palma, C, Giovarelli, M, Bizzozero, L, Pambianco, S, Di Renzo, I, Zecchini, S, Moscheni, C, Vantaggiato, C, Procacci, P, Clementi, E & Perrotta, C 2016, 'Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin', Oncotarget, vol. 7, no. 18, pp. 24995-25009. https://doi.org/10.18632/oncotarget.8735
Cervia, Davide ; Assi, Emma ; De Palma, Clara ; Giovarelli, Matteo ; Bizzozero, Laura ; Pambianco, Sarah ; Di Renzo, Ilaria ; Zecchini, Silvia ; Moscheni, Claudia ; Vantaggiato, Chiara ; Procacci, Patrizia ; Clementi, Emilio ; Perrotta, Cristiana. / Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin. In: Oncotarget. 2016 ; Vol. 7, No. 18. pp. 24995-25009.
@article{4cb7a47cb2cf4aa8ad9b27abe572d433,
title = "Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin",
abstract = "The sphingolipid metabolising enzyme Acid Sphingomyelinase (A-SMase) has been recently shown to inhibit melanoma progression and correlate inversely to tumour grade. In this study we have investigated the role of A-SMase in the chemo-resistance to anticancer treatment using mice with melanoma allografts and melanoma cells differing in terms of expression/activity of A-SMase. Since autophagy is emerging as a key mechanism in tumour growth and chemo-resistance, we have also investigated whether an action of A-SMase in autophagy can explain its role. Melanoma sensitivity to chemotherapeutic agent cisplatin in terms of cell viability/apoptosis, tumour growth, and animal survival depended directly on the A-SMase levels in tumoural cells. A-SMase action was due to inhibition of autophagy through activation of Akt/mammalian target of rapamycin (mTOR) pathway. Treatment of melanoma-bearing mice with the autophagy inhibitor chloroquine restored sensitivity to cisplatin of tumours expressing low levels of A-SMase while no additive effects were observed in tumours characterised by sustained A-SMase levels. The fact that A-SMase in melanomas affects mTOR-regulated autophagy and plays a central role in cisplatin efficacy encourages pre-clinical testing on the modulation of A-SMase levels/activity as possible novel anti-neoplastic strategy.",
keywords = "A-SMase, Autophagy, Chemo-resistance, Melanoma, mTOR",
author = "Davide Cervia and Emma Assi and {De Palma}, Clara and Matteo Giovarelli and Laura Bizzozero and Sarah Pambianco and {Di Renzo}, Ilaria and Silvia Zecchini and Claudia Moscheni and Chiara Vantaggiato and Patrizia Procacci and Emilio Clementi and Cristiana Perrotta",
note = "L. Bizzozzero non risulta correttamente affiliata in questa pubblicazione.",
year = "2016",
month = "5",
day = "1",
doi = "10.18632/oncotarget.8735",
language = "English",
volume = "7",
pages = "24995--25009",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "18",

}

TY - JOUR

T1 - Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin

AU - Cervia, Davide

AU - Assi, Emma

AU - De Palma, Clara

AU - Giovarelli, Matteo

AU - Bizzozero, Laura

AU - Pambianco, Sarah

AU - Di Renzo, Ilaria

AU - Zecchini, Silvia

AU - Moscheni, Claudia

AU - Vantaggiato, Chiara

AU - Procacci, Patrizia

AU - Clementi, Emilio

AU - Perrotta, Cristiana

N1 - L. Bizzozzero non risulta correttamente affiliata in questa pubblicazione.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The sphingolipid metabolising enzyme Acid Sphingomyelinase (A-SMase) has been recently shown to inhibit melanoma progression and correlate inversely to tumour grade. In this study we have investigated the role of A-SMase in the chemo-resistance to anticancer treatment using mice with melanoma allografts and melanoma cells differing in terms of expression/activity of A-SMase. Since autophagy is emerging as a key mechanism in tumour growth and chemo-resistance, we have also investigated whether an action of A-SMase in autophagy can explain its role. Melanoma sensitivity to chemotherapeutic agent cisplatin in terms of cell viability/apoptosis, tumour growth, and animal survival depended directly on the A-SMase levels in tumoural cells. A-SMase action was due to inhibition of autophagy through activation of Akt/mammalian target of rapamycin (mTOR) pathway. Treatment of melanoma-bearing mice with the autophagy inhibitor chloroquine restored sensitivity to cisplatin of tumours expressing low levels of A-SMase while no additive effects were observed in tumours characterised by sustained A-SMase levels. The fact that A-SMase in melanomas affects mTOR-regulated autophagy and plays a central role in cisplatin efficacy encourages pre-clinical testing on the modulation of A-SMase levels/activity as possible novel anti-neoplastic strategy.

AB - The sphingolipid metabolising enzyme Acid Sphingomyelinase (A-SMase) has been recently shown to inhibit melanoma progression and correlate inversely to tumour grade. In this study we have investigated the role of A-SMase in the chemo-resistance to anticancer treatment using mice with melanoma allografts and melanoma cells differing in terms of expression/activity of A-SMase. Since autophagy is emerging as a key mechanism in tumour growth and chemo-resistance, we have also investigated whether an action of A-SMase in autophagy can explain its role. Melanoma sensitivity to chemotherapeutic agent cisplatin in terms of cell viability/apoptosis, tumour growth, and animal survival depended directly on the A-SMase levels in tumoural cells. A-SMase action was due to inhibition of autophagy through activation of Akt/mammalian target of rapamycin (mTOR) pathway. Treatment of melanoma-bearing mice with the autophagy inhibitor chloroquine restored sensitivity to cisplatin of tumours expressing low levels of A-SMase while no additive effects were observed in tumours characterised by sustained A-SMase levels. The fact that A-SMase in melanomas affects mTOR-regulated autophagy and plays a central role in cisplatin efficacy encourages pre-clinical testing on the modulation of A-SMase levels/activity as possible novel anti-neoplastic strategy.

KW - A-SMase

KW - Autophagy

KW - Chemo-resistance

KW - Melanoma

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=84967261194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967261194&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8735

DO - 10.18632/oncotarget.8735

M3 - Article

VL - 7

SP - 24995

EP - 25009

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 18

ER -